Friday, 16 Nov 2018

You are here

Health Canada Issues Acetaminophen Advisory

Yesterday Health Canada announced it “is taking additional steps to minimize the risk of liver damage and improve acetaminophen safety,” citing the findings of a government review that underscored the possibility of accidental overdose.

Of the 4 billion doses of acetaminophen sold in Canada each year, there were 4000 hospitalizations for acetaminophen overdose - 20% of these were using doses in excess of 4000 mg per day. A Statistics Canada database recorded 253 accidental deaths and nearly 300 suicides between 2000 and 2009 where acetaminophen was a major or contributing cause of death.

Acetaminophen By the Numbers

4 billion — Number of doses of acetaminophen sold in Canada each year

475 — The number of different acetaminophen products currently authorized for marketing in Canada

4 — Number of grams of acetaminophen in the recommendation maximum daily dose

10 — Number of grams of acetaminophen per day that can lead to liver damage

4,000 — Number of hospitalizations in Canada each year for acetaminophen overdose

20 — Percentage of hospitalizations for acetaminophen overdose due to people exceeding the recommended dose unintentionally

250 — Number of cases of serious liver injury per year in Canada related to acetaminophen

50 — Percentage of cases of serious liver injury associated with unintentional overdoses

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs. 

Low Short-Term Risks of NSAIDs in High Risk Patients

JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-37 days of exposure). 

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.

Anti-phospholipid Antibodies and Myocardial Infarction.

The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal Medicine reports.

Update on Immune Checkpoint Inhibitor Toxicity

JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.